Pharmaceutical

Group at a Glance

  • 23 members
  • 18 members have PhDs or MDs

What Matters to Our Clients

Deep Understanding of Technology and Industry Insight

From first-hand experience, members of our Pharmaceutical Group understand the importance of patents, trademarks, and trade secrets to pharmaceutical companies. Comprised of attorneys who have both conducted research at and represented pharmaceutical giants and startups alike, our group also understands the interaction of patents with a range of FDA issues such as patent term extensions, non-patent exclusivities, Orange Book listing requirements, Hatch-Waxman issues, and ANDA (Abbreviated New Drug Application) litigation. Our attorneys also are experienced in handling a wide variety of licensing issues and work with our clients to license in as well as license out technology.

Our clients appreciate working with a team with the scientific training to grasp complex matters quickly. Most of our members have PhDs, and several have medical degrees. Academic backgrounds include: organic chemistry, medicinal chemistry, process chemistry, formulation chemistry, chemical biology, chemical engineering, molecular biology, biochemistry, medical biophysics, immunology, molecular genetics, toxicology, and epidemiology.

Broad Base of Experience

Intellectual property law directly shapes the business of our pharmaceutical clients. Their lifeblood is derived from maximizing the terms of their patents, and the industry’s emphasis on trademarks is perhaps second only to that of the consumer products industry.

While many law firms choose to specialize their pharmaceutical IP practice on one area or type of customer profile, our clients value the agility and creativity that our group offers. Big Pharma or startup, branded or generic, active ingredient or finished product, we have the experience to thoroughly address our clients’ requirements.

Services of our Pharmaceutical Group include: freedom to operate, due diligence, license negotiation, development, prosecution, and analysis of patent and trademark portfolios, patent interferences, counseling on strategic planning issues, lifecycle management, patent term extensions, Orange Book listing strategies, and ANDA litigation.

Areas of Expertise

Examples of our group's areas of expertise include:

Contract All | Expand All

-
ANDA litigation
-
Bioinformatics
-
Biopharmaceuticals
  • Antibodies
  • Oligonucleotide chemistry
  • Peptide chemistry
  • Protein chemistry
  • RNAi
-
Chemistry
  • Combinatorial chemistry
  • Formulations
  • Medicinal chemistry
  • Metabolites
  • Polymorphs
  • Process chemistry
-
Drug discovery
  • Drug delivery systems
  • High throughput screening
-
Generic drug issues
-
Hatch-Waxman Issues
-
Lifecycle management
  • Joint venture strategies
  • Licensing
  • Market entry strategies
-
Orange Book listings & strategies
-
Patent term extensions
-
Pharmacogenomics
-
Toxicology
View All Group Members

-
Representative Group Clients
  • Jefferies LLC
  • OrbiMed
  • Oxford Bioscience Partners
  • Progenics Pharmaceuticals Inc.
  • Shire Pharmaceuticals
  • Synta Pharmaceuticals, Inc.
Newsstand
April 17, 2014 - Chelsea Loughran quoted in The Scientist on first awarded CRISPR-Cas9 patent

April 16, 2014 - Chelsea Loughran quoted in MIT Tech Review on first awarded patent for engineered CRISPR-Cas9 system

March 2014 - CRISPR/Cas-9: An Exciting Addition to Genomic Editing

March 5, 2014 - Doug Wolf featured as the Entrepreneur.com expert for the month of March

February 2014 - The New World of Diagnostic Testing Post-Myriad

Novozymes v. DuPont Nutrition (decided 7/22/13) - Written Description Precludes Fishing Expedition

February 5, 2014 - WOLF GREENFIELD WEBCAST REPLAY: CRISPR/Cas-9 and the IP Landscape for a Revolutionary New Technology

January 30, 2014 - "Intellectual Property for Startups: Making It Work on a Limited Budget" Webinar - Replay Now Available

December 2013 - Recovering Patent Life with Patent Term Extension

October 21, 2013 - Twenty Wolf Greenfield Attorneys Selected to 2013 Massachusetts Super Lawyers List

Dey, L.P. v. Sunovion Pharmaceuticals (5/20/13) - Consider Confidentially Measures When Using Inventions in Clinical Trials

Aventis Pharma v. Amino Chemicals (decided 5/20/13 - Claim Terms Can Be Construed to Have More than One Meaning

October 18, 2013 - IP ALERT - European Patent Office Reverses Two-Year Deadline on Divisional Applications

October 17, 2013 - WOLF GREENFIELD SEMINAR: Strategically Building a Valuable Worldwide Patent Portfolio - Replay Now Available

August 15, 2013 - Ten Wolf Greenfield Attorneys Named to The Best Lawyers in America 2014 List

August 2013 - Rainmaker Q&A: Wolf Greenfield's Edward Gates

Santarus v. Par Pharmaceutical (9/4/12) - Federal Circuit Addresses Written Description for Negative Claim Limitations and Clarifies Obviousness for CIP Applications

June 17, 2013 - Greg Corbett quoted in Law360 on pay-for-delay settlements.

June 14, 2013 - IP ALERT - Supreme Court Says Isolated Natural DNA Not Patent Eligible But Leaves Open Questions Regarding Synthetic DNAs

June 14, 2013 - Patrick Waller quoted in Law360 on gene patenting.

June 2013 - Wolf Greenfield Attorneys Named to IAM 1000 World’s Leading Patent Practitioners List

Wrigley Jr. Co. v. Cadbury Adams (6/22/12) - Influence of Secondary Considerations in Overcoming Prima Facie Case of Obviousness

April 24, 2013 - WOLF GREENFIELD WEBINAR: Key Patent Litigation Decisions and the ITC as Alternate Forum - Replay Now Available

April 2013 - Wolf Greenfield Tops the Boston Business Journal’s List of Largest Area Intellectual Property Law Firms

April 10, 2013 - Larry Green quoted in Biopharminsight on Idenix

April 10, 2013 - Rob Walat quoted in Mass High Tech

March 22, 2013 - Ed Walsh quoted on "first-inventor-to-file" changes

March 22, 2013 - Patrick Waller quoted on the "First-Inventor-to File" system

March 11, 2013 - Patrick Waller quoted in Law360 on first-to-file patent system

February 21, 2013 - Wolf Greenfield Attorney Recognized for Pro Bono Service by Women’s Bar Foundation

February 12, 2013 - Deadline approaches for patent protections

February 5, 2013 - Wolf Greenfield Named Elite Trademark Law Firm in World Trademark Report 1000

January 29, 2013 - Preparing for the “First Inventor to File” Transition

January 28, 2013 - ‘Super Lawyer’ digs Chelsea, Admiral’s Hill Home

January 18, 2013 - Ed Walsh was quoted in a Law360 article on Patent Reform

October 22, 2012 - Fifteen Wolf Greenfield Lawyers Highlighted in 2012 Massachusetts Super Lawyers List

October 18, 2012 - WOLF GREENFIELD SEMINAR: What You Need to Know to Prepare for the "First Inventor to File" Transition - Replay Now Available

September 19, 2012 - Eleven Wolf Greenfield Attorneys Selected for 2013 Best Lawyers in America®

September 6, 2012 - Federal Circuit Establishes New Standard on Divided Infringement and Inducement

July 27, 2012 - Chelsea Loughran quoted in Law360 on the new First-To-File rules

June 2012 - Wolf Greenfield Named to IAM 1000 World’s Leading Patent Practitioners List

June 2012 - GBLS Recognizes Wolf Greenfield with 2012 Associates Drive Award

Teva v. AstraZeneca (decided 12/1/11) - Winning Priority Contest Requires Prior Inventor to Appreciate Invention’s Purpose

In Re Hyon (5/24/12) - Federal Circuit Clarifies Substantial Evidence Standard on Appeal for Questions of Motivation to Combine

In re MSTG, Inc (4/9/12) - No Settlement Negotiations Privilege

Aventis Pharma v. Hospira (4/9/12) - Federal Circuit Finds Inequitable Conduct For Failure To Cite Prior Art Under the Heightened Therasense Standard

AFT Trust. v. J&L Fiber (4/3/12) - Prosecution History Can Be Used During Claim Construction

March 26, 2012 - IP ALERT - Supreme Court Invalidates Process Claims in Prometheus

Marine Polymer v. HemCon (decided 3/15/12) - Intervening Rights Cannot Be Triggered by Argument Alone in Reexaminations

In re Erik P. Staats and Robin P. Lash (3/5/2012) - Federal Circuit Rejects Restrictions on Broadening Claims in Reissue Applications

ClearValue v Pearl River Polymers (2/17/12) - A Range With No Special Features Can Anticipate Sub-range

In re Google, Inc. (decided 2/6/12) - Substance of Emails Determines Attorney-Client Privilege Protection

January 31, 2012 - Navigating Patent Eligibility for Process Claims

December 2011 - Neil Ferraro Named 2012 Boston Patent Law Association President

January 3, 2012 - Wolf Greenfield Welcomes 2012 Promoting Seven Lawyers to New Positions

November 2011 - America Invents Act: The Implications of Patent Reform

October 12, 2011 - Wolf Greenfield Sponsored MIT Forum Event on October 12

In re Stepan (decided 10/5/11) - BPAI Triggers “New Ground of Rejection” When Changing Statutory Basis of Rejection

September 2011 - America Invents Act – Patent Reform is Finally Here

September 9, 2011 - IP ALERT—Senate Endorses The Long-Awaited Patent Reform

Markem-Imaje Corp. v. Zipher Ltd (decided 9/9/11) - Same Claim Terms Can Have Different Meanings Within Different Limitations

AIA Engineering v Magotteaux (decided 8/31/11) - Federal Circuit Muddies Reissue Application Practice

Unigene Laboratories v. Apotex (decided 8/25/11) - Follow-on Pharmaceutical Formulation Found Non-Obvious

Duramed v. Paddock (decided 7/21/11) - Prosecution History Estoppel Bars Allegations of Infringement Under Doctrine of Equivalents

February 25, 2011 - Managing the Pace of Patent Applications

February 17, 2011 - WOLF GREENFIELD SEMINAR: Managing IP Risks: The Importance of Obtaining Freedom to Operate Guidance - presentation now available

January 10, 2011 - Post Ariad: Written Descriptions For Patents

January 1, 2011 - Wolf Greenfield filed 2,749 patent applications and 688 trademark applications in 2010.

December 2010 - Wolf Greenfield was ranked #1 in number of patents filed and number of patent attorneys in Mass High Tech’s annual survey

August 25, 2010 - Presentation to entrepreneurs at MassChallenge

August 22, 2010 - Hunter Baker, Ed Gates and Chelsea Loughran presented at the American Chemical Society’s Fall National Meeting

August 20, 2010 - BBJ survey ranks Wolf Greenfield #1 in patent attorneys, patents filed and patents obtained

June 2010 - Bilski ruling from US Supreme Court

July 2, 2010 - Industry Groups, Practitioners React To High Court Decision on Method Patents

July 7, 2010 - A Wolf Greenfield Webinar: Forecasting the Future of Method Patents Post-Bilski — archived replay of webinar now available

June 28, 2010 - CLIENT ALERT— Supreme Court Leaves Door Open to Business Method Patents

June 17, 2010 - WOLF GREENFIELD SEMINAR: Strategically Building and Monetizing a Patent Portfolio - replay now available

June 4, 2010 - Salix's polymorph patents for Xifaxan may be vulnerable to future challenge, experts say

May 19, 2010 - “Cephalon settlement with generic makers in Nuvigil patent suits could be delayed by ongoing antitrust litigation - experts”

April 16, 2010 - Patent Applications Must Have Separate Written Description

April 14, 2010 - CLIENT ALERT— Federal Circuit Decision Reaffirms Separate Written Description Requirement

April 2, 2010 - CLIENT ALERT— The New Biosimilar Pathway: Biologics Price Competition and Innovation Act

March 31, 2010 - Prolonging Patent: Under Wyeth, Many Patent Terms Will Be Recalculated

March 29, 2010 - Court Backs Lilly In Patent Case

February 19, 2010 - More Organizations Ask PTO to Recalculate Term Adjustments

October 15, 2009 - CLIENT ALERT — USPTO Rescinds Controversial Rules Restricting Patent Applications

October 2009 - Court Case on Patent Delays Holds Appeal for Industry

September 25, 2009 - Lack of timing awareness can mean missed revenue

September 24, 2009 - CLIENT ALERT — Federal Circuit Confirms Diagnostic and Therapeutic Methods Can be Patentable Subject Matter

May 4, 2009 - C. Hunter Baker, MD, PhD, joins Wolf Greenfield as Counsel in our Pharmaceutical Group

March 25, 2009 - CLIENT ALERT — Federal Circuit Decision on Controversial PTO Rules

February 2009 - Maximizing Intellectual Property Value in Tough Economic Times- Seminar replay now available

November 12, 2008 - Navigating Technology Collaborations and Joint Ventures—Wolf Greenfield seminar

August 2008 - Wolf Greenfield wins three more years of patent protection for Shire Pharmaceuticals' ELAPRASE treatment

February 7, 2008 - An Entrepreneur's Guide to the Intellectual Property Galaxy

September 2007 - Pharma Patents and Licensing Are Transformed by Landmark 2007 Court Decisions, Wolf Greenfield Lawyer Tells American Chemical Society

March 29, 2007 - Wolf Greenfield Client Diomed Holdings Wins $12.5 Million Award in Patent Case - Jury Finds Two Defendants Infringed Patent for Varicose Vein Treatment

March 21, 2007 - Wolf Greenfield Names Oyer President and Managing Partner - Lawyer/Scientist Takes Reins at Boston Intellectual Property Law Firm

November 2006 - Accelerated Examination of Patent Applications: Too Good To Be True?

Q&A Booklet - Q&A on Patents

Q&A Booklet - Q&A on Intellectual Property Litigation

Q&A Booklet - Q&A on Licensing and Transactions